

**PRELIMINARY AMENDMENT
CONT of USSN 09/700,397**

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) ~~A substantially purified~~ An isolated form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. ~~1, 4, 6, 9 or 12~~ 3, 4, 8, 11 or 14, homologue thereof, fragment thereof or homologue of the fragment.

Claim 2. (Currently Amended) ~~A~~ The polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NOS. ~~1, 4, 6, 9 or 12~~ 3, 4, 8, 11 or 14.

Claim 3. (Currently Amended) A cDNA molecule encoding the polypeptide ~~according to claim 1~~ comprising the amino acid sequence shown in SEQ ID NOS. 3, 4, 8 or 11, homologue thereof, fragment thereof or homologue of the fragment.

Claim 4. (Currently Amended) ~~A~~ The cDNA molecule according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. ~~2, 5, 7, 10 or 13~~ 1, 5, 6 or 9, or a fragment cDNA selectively hybridized to the cDNA.

Claim 5. (Currently Amended) ~~A~~ The cDNA molecule according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. ~~3, 8, 11 or 14~~ 2, 7 or 10, or a fragment cDNA selectively hybridized to the cDNA.

Claim 6. (Currently Amended) A replication or expression vector ~~carrying~~ comprising the cDNA according to any one of claims 3 to 5.

Claim 7. (Original) A host cell transformed with the replication or expression vector according to claim 6.

**PRELIMINARY AMENDMENT
CONT of USSN 09/700,397**

Claim 8. (Original) A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.

Claim 9. (Original) A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.

Claim 10. (Original) A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.